Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

International price comparisons for novel and follow-on drugs.

Ridley DB.

Value Health. 2007 Nov-Dec;10(6):510-1; discussion 512-3. No abstract available.

2.
3.
4.

Health technology assessment and economic evaluation across jurisdictions.

Simoens S.

Value Health. 2010 Sep-Oct;13(6):857-9. doi: 10.1111/j.1524-4733.2010.00756.x. Epub 2010 Aug 4. No abstract available.

5.

Better pharmaceutical price comparison studies are needed for meaningful evaluation of price-control policies.

[No authors listed]

Value Health. 2008 Jan-Feb;11(1):129-30. doi: 10.1111/j.1524-4733.2007.00300.x. Epub 2007 Dec 27. No abstract available.

6.

A cost-effectiveness approach to drug subsidy and pricing in Australia.

Birkett DJ, Mitchell AS, McManus P.

Health Aff (Millwood). 2001 May-Jun;20(3):104-14.

7.

The high cost of medicines in Ireland. Is it time to change the pricing mechanism?

Tilson L, McGowan B, Bennett K, Barry M.

Eur J Health Econ. 2004 Dec;5(4):341-4.

PMID:
15452737
8.

An Italian perspective: studying the cost-effectiveness of sofosbuvir before completion of national price negotiations.

Messori A, Maratea D, Fadda V, Gatto R, Trippoli S.

Eur J Gastroenterol Hepatol. 2014 Jul;26(7):813-4. doi: 10.1097/MEG.0000000000000107. No abstract available.

PMID:
24901827
9.

Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.

Schlette S, Hess R.

Issue Brief (Commonw Fund). 2013 Oct;29:1-9.

PMID:
24171232
10.

Propaganda or the cost of innovation? Challenging the high price of new drugs.

Ghinea N, Lipworth W, Kerridge I.

BMJ. 2016 Mar 11;352:i1284. doi: 10.1136/bmj.i1284. Review. No abstract available.

PMID:
26968991
11.

[International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].

Vacca C, Acosta A, Rodriguez I.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S16-9. doi: 10.1016/j.jval.2011.05.034. Spanish.

12.

Health technology assessment and economic evaluation: arguments for a national approach.

Vale L.

Value Health. 2010 Sep-Oct;13(6):859-61. doi: 10.1111/j.1524-4733.2010.00765.x. Epub 2010 Aug 4. No abstract available.

13.

Rescuing health care: the price of health.

Eckholm E.

N Y Times Web. 1991 May 2:A1, B12. No abstract available.

PMID:
11646244
14.

Cost containment, drugs and community health.

Wiesner D.

Aust J Public Health. 1995 Dec;19(6):641-2. No abstract available.

PMID:
8616208
15.

Pricing and reimbursement of drugs in Ireland.

Barry M, Tilson L, Ryan M.

Eur J Health Econ. 2004 Jun;5(2):190-4.

PMID:
15452757
16.

[May drugs be a cost-effective investment in Spanish health system?].

Soto J, Olivella P.

Med Clin (Barc). 2001 Nov 17;117(16):622-4. Spanish. No abstract available.

PMID:
11714470
17.

[Networking nursing in the national and international context: requirements under economic factors].

Conrad J.

Pflege Z. 2010 Sep;63(9):544-7. German. No abstract available.

PMID:
20922980
18.

The role of economic evaluation in the pricing and reimbursement of medicines.

Drummond M, J├Ânsson B, Rutten F.

Health Policy. 1997 Jun;40(3):199-215.

PMID:
10168752
19.

[New drug agreement stands. No more deductions starting next year].

Schmidt K.

MMW Fortschr Med. 2007 Nov 22;149(47):56-7. German. No abstract available.

PMID:
18069140
20.

Prices and availability of biopharmaceuticals: an international comparison.

Danzon PM, Furukawa MF.

Health Aff (Millwood). 2006 Sep-Oct;25(5):1353-62.

Supplemental Content

Support Center